Stockscreener 앱 받기
1.86
6.29%
0.11
시간 외 거래:
1.89
0.03
+1.61%
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GANX|Gain Therapeutics Inc|Price:1.750|Chg%:-0.070 - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 stock options - Stock Titan
Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (NASDAQ: GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike - Stock Titan
Gain Therapeutics Extends Cash Runway Into 2027 Operations - TipRanks
Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO - Moomoo
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com - Investing.com South Africa
Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans - TradingView
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 - Investing.com
Gain Therapeutics (NASDAQ: GANX) sees cash funding into Q2 2027 - Stock Titan
Gain Therapeutics advances Parkinson's drug rex... - Pluang
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - marketscreener.com
Gain Therapeutics Reports 81% Biomarker Drop in Some Patients - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Gain Therapeutics (GANX) Q1 2026 earnings summary - Quartr
Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary - Quartr
Gain Therapeutics (GANX) Proxy filing Summary - Quartr
Gain Therapeutics (GANX) Q4 2025 earnings summary - Quartr
GANX Q1 2026 Earnings: Narrower Loss Per Share Beats Estimates Amid Pre-Revenue PhaseQuarterly Financial Update - dars.gov.et
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - BioBuzz
With new FDA green light for developer, Parkinson’s clinical trial to launch soon - Parkinson's News Today
Gain Therapeutics Inc. (GANX) Declines Sharply as Key Support Level Comes into FocusElliott Wave Count - dars.gov.et
Gain Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss but Shares DeclineGuidance Update - dars.gov.et
Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Good GAIN - Moomoo
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics Price Target Maintained With a $5.00/Share by BTIG - Moomoo
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Gain Therapeutics (GANX) Jumps 13% to $1.98 – Support and Resistance Levels in FocusPSAR Stop - dars.gov.et
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease - marketscreener.com
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial By Investing.com - Investing.com Nigeria
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug - Investing.com
1.97%
0.83%
자본화:
|
볼륨(24시간):